Michał Jakubczyk, Maciej Niewada, Robert Plisko, Magdalena Władysiuk, Michał Jachimowicz, Cezary Pruszko, Katarzyna Wepsięć, Joanna Lis
What matters in treating non-oncological rare diseases?—Eliciting experts’ preferences in Poland with PAPRIKA
Special Issue: Multiple Criteria Decision Making in Health and Medicine Volume 29, Issue1-2,
January-April 2022
ARTICLE

Magdalena Władysiuk, Robert Plisko
Innowacje. Fundusz medyczny. (Innovations. Medical fund.)
Kraków, 2021
REPORT (PL)

—

Magdalena Władysiuk, Monika Małowicka, Kinga Kawaler, Monika Szałańska, Katarzyna Mazur, Paulina Rolska-Wójcik
Szczepienia przeciwko pneumokokom u dzieci w Polsce – stan faktyczny na 2020 rok. Aktualizacja raportu z 2018 roku.
Kraków, 2021
Summary (PL)| Infographic (PL)

Moorkens E, Godman B, Plisko R et al. (2021) The Expiry of Humira^® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. Front. Pharmacol. 11:591134. doi: 10.3389/fphar.2020.591134,
ARTICLE

—

Robert Plisko, Magdalena Władysiuk, Marta Polkowska, Joanna Lis Indirect costs of atopic dermatitis (AD) – systematic review and polish perspective, październik 2020
ARTICLE

—

Szczepienia przeciw rotawirusom – rekomendacje kliniczne i refundacyjne (Rotavirus vaccinations – clinical and reimbursement recommendations) September 2020
Folder (PL)
Analiza progowa opłacalności szczepienia przeciw infekcji rotawirusowej w zależności od terminu zakończenia cyklu szczepień (Threshold analysis of the cost-effectiveness of vaccination against rotavirus infection depending on the date of completion of the vaccination cycle)
Results of the threshold analysis (PPT PL)

—

Wielokryterialna analiza decyzyjna (MCDA), Konsorcjum MCDA. Multi-criteria Decision Analysis w ocenie technologii stosowanych w nieonkologicznych chorobach rzadkich
(Multicriteria decision analysis (MCDA), MCDA Consortium. Multi-criteria Decision Analysis in the evaluation of technologies used in non-oncological rare diseases). Warszawa 2020. Poland
REPORT (PL)

—

Anita Stożek-Tutro, Magdalena Monica, Paulina Rolska-Wójcik, Katarzyna Czok, Monika Szałańska Tętnicze nadciśnienie płucne. Wpływ choroby na pacjentów, opiekunów i społeczeństwo. Kraków 2020 REPORT (PL)

Elżbieta Łukomska, Magdalena Władysiuk, Paulina Rolska, etc.
Droga do Value-Based Healthcare. VBHC w teorii oraz praktyce (en. Road to Value-Based Healthcare)
June 2019 REPORT

Magdalena Władysiuk, Paulina Rolska, Kinga Fiałek, Monika Małowicka, Katarzyna Mazur, Monika Szałańska, Maciej Ziobro
Szczepienia przeciwko pneumokokom u dzieci w Polsce – stan faktyczny (en. Pneumococcal vaccination among children in Poland)
December 2018 Summary

Tomasz Fundament, Paul R. Eldridge, Alexander L. Green, Alan L. Whone, Rod S. Taylor, Adrian C. Williams, W. M. Michael Schuepbach
Deep Brain Stimulation for Parkinson’s Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis
Full text

Jahnz-Różyk K, Kucharczyk A, Warchoł M, Radziwilska-Muc A, Władysiuk M, Plisko R
The costs of asthma in Poland in 2012
WWW

Anna Tytuła, Monika Gumola, Sylwia Krakowska
Analysis of drugs LABA and LAMA. The availability of the treatment for the patient – the perspective of the payer in Poland and in selected EU countries
Executive Summary (polish) PDF      Annex to the Report: Map of drug reimbursement LABA + LAMA in Europe (polish) PDF

Maria Libura, Magdalena Władusiuk, Monika Małowicka, Edyta Grabowska, Małgorzata Gałązka-Sobotka, Jerzy Gryglewicz
Rare diseases in Poland 2015
Report (polish) PDF

Władysiuk M, Plisko R, Hetnał E, Pochopień M, Gad B, Kostrzewska K, Adamski J, Bogusławski S, Mikułowska M,
RSA in Drugs Reimbursement System in Poland and Abroad
Full Report (polish)  PDF

Łanda K, Kordecka A, Ryś P, Plisko R, Pruszko C, Wierzba W, Rolska P, Łabuda J, Kalinowska A,
Innovative Oncological Care Fund
Full Report (polish) PDF

Wojciechowski P, Niemczyk-Szechowska P, Olewińska E, Jaros P, Mierzejewska B, Skarżyńska-Duk J, Małecki MT, Ryś P.,
Clinical efficacy and safety of insulin aspart compared with regular human insulin in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis
REPORT
Pol Arch Med Wewn. 2015 Mar 31;125(3):141-51. Epub 2015 Jan 30

Rys P, Wojciechowski P, Rogoz-Sitek A, Niesyczyński G, Lis J, Syta A, Malecki MT,
Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus
REPORT
Acta Diabetol. 2015 Jan 14. [Epub ahead of print]

Snarski E, Szmurło D, Hałaburda K, Król M, Urbanowska E, Milczarczyk A, Franek E, Wiktor-Jedrzejczak W,
An economic analysis of autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of new onset type 1 diabetes
REPORT
Acta Diabetol. 2015 Mar 6. [Epub ahead of print]

Leśniowska J., Schubert A., Wojna M., Skrzękowska-Baran I., Fedyna M.,
Costs of diabetes and its complications in Poland
REPORT

Kobierski J., Hałdaś M., Władysiuk M.,
Hepatitis C – the implications and the need for change in the health care system in Poland
REPORT

Drzał R., Szmurło D., Parker M., Plisko R., Władysiuk M.,
Can We Determine the Optimal Cycle Length for Which Half-Cycle Correction Should Always Be Applied?
REPORT

Godman B, Malmström RE, Diogene E, Gray A,  Władysiuk M, Zeng W, Gustafsson LL. (et all.)
Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?
REPORT
Expert Rev Clin Pharmacol. 2015 Jan;8(1):77-94. doi: 10.1586/17512433.2015.990380.

Wladysiuk M., Szmurlo D., Kostrzewska K., Adamski J., Drzal R., Plisko R., Zuchnicka R., Dobosz K., Wolinska N.,
Indirect costs in health technology assessment. Methodology, pilot study and recommendations
REPORT

Władysiuk M., Jaros P., Kobierski J., Hałdaś M., Gąszcz K., Krzystek J.,
Hepatitis C – the need for changes in the organization of the health care system
REPORT

Szmurło D., Fundament T., Ziobro M., Kruntorádová K., Doležal T., Głogowski C.,
Costs of multiple sclerosis – extrapolation of Czech data to Polish patients
Expert Rev Pharmacoecon Outcomes Res. 2014 Apr 7
ABSTRACT, FULL TEXT

Rys P, Wojciechowski P, Siejka S, Małecki P, Hak L, Malecki MT,
A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus-a systematic review and meta-analysis
REPORT
Int J Clin Pract. 2014 Mar;68(3):304-13. doi: 10.1111/ijcp.12337. Epub 2014 Jan 28

Godman B, Malmström RE, Diogene E, Jayathissa S, Wladysiuk M, van Woerkom M, Zara C, Gustafsson LL., (et all.)
Dabigatran – a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs
REPORT
Front Pharmacol. 2014 Jun 10;5:109. doi: 10.3389/fphar.2014.00109. eCollection 2014. Review

Rickard E. Malmström, Brian B.Godman, MadalenaWładysiuk et al.
Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs
Frontiers in Pharmacology 2013; 4, 10.3389/fphar.2013.00039
ABSTRACT, FULL TEXT

Czech M, Opolski G, Zdrojewski T, Dubiel JS, Wizner B, Bolisęga D, Fedyk-Łukasik M, Grodzicki T
Costs of heart failure in Poland from payer’s perspective. The assessment program of diagnostics, treatment and costs in patients with heart failure in randomly selected outpatient and inpatient institutions at a basic, provincial and specialist level.
Kardiologia Polska 2013; 71, 3: 224-232

ABSTRACT, FULL TEXT

Godman B, Finlayson A E, Cheema P K, Zebedin-Brandl E, Wladysiuk M, van Woerkom M, Wong-Rieger D, Zara C, Ali R,Gustafsson L L, (et all.)
Personalizing health care: feasibility and future implications
PDF

Małecka-Massalska T, Chara K, Gołębiowski P, Władysiuk M, Smoleń A, Kurylcio A, Zuchora B, Zubrzycki J, Orłowska-Kowalik G, Lupa-Zatwarnicka K, Polkowski W.,
Altered tissue electrical properties in women with breast cancer-preliminary observations
REPORT
Ann Agric Environ Med. 2013;20(3):523-7

Wladysiuk M, Tabor A, Godman B.,
‘HTA for Crisis’: sharing experiences during the 7th EBHC Symposium
REPORT   Expert Rev Pharmacoecon Outcomes Res. 2013 Feb;13(1):47-9. doi: 10.1586/erp.12.92

Wojciechowski P, Lipowska A, Rys P, Ewens KG, Franks S, Tan S, Lerchbaum E, Vcelak J, Attaoua R, Straczkowski M, Azziz R, Barber TM, Hinney A, Obermayer-Pietsch B, Lukasova P, Bendlova B, Grigorescu F, Kowalska I, Goodarzi MO; GIANT Consortium, Strauss JF 3rd,
McCarthy MI, Malecki MT,
Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a systematic review and meta-analysis
REPORT
Diabetologia. 2012 Oct;55(10):2636-45. doi: 10.1007/s00125-012-2638-6. Epub 2012 Jul 18. Review. Erratum in: Diabetologia. 2012 Oct;55(10):2858-9

Szmurło D, Deryło Ł, Ryś P, Władysiuk M
The economics of therapy with bypassing drugs in haemophilia A complicated by an inhibitor – activated prothrombin complex concentrates (APCC) versus recombinant activated factor VII (rFVIIa)
Polski Merkuriusz Lekarski, 2011, XXX, 177, 202
ABSTRACT

Rys P, Pankiewicz O, Łach K, Kwaskowskia A, Skrzekowska-Baran I, Malecki MT
Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: A systematic review
Diabetes & Metabolism 2011
ABSTRACT

Wladysiuk M, Araszkiewicz A, Godman B, Szabert K, Barbui C, Haycox A
Influence of Patient Co-Payments on Atypical Antipsychotic Choice in Poland: Implications Once Generic Atypicals are Available
Applied Health Economics & Health Policy: 2011 Mar;9(2):101-110
ABSTRACT

Godman B, Shrank W, Andersen M, Berg Ch, Bishop I, Burkhardt T, Garuoliene K, Herholz H, Joppi R, Kalaba M, Laius O, Lonsdale J, Malmström RE, Martikainen JE, Samaluk V, Sermet C, Schwabe U, Teixeira I, Tilson L, CankatTulunay F, Vlahović-Palčevski V, Wendykowska K, Wettermark B, Zara C,Gustafsson LL
Policies to enhance prescribing efficiency in Europe: findings and future implications
Frontiers in Pharmacology 2011, 1(141):1-16
FULL TEXT

Szmurło D, Schubert A, Kostrzewska K, Ryś P, Skrzekowska-Baran I,
Economic analysis of the implementation of guidelines for type 2 diabetes control developed by Diabetes Poland: what increase in costs is justified by clinical results?
REPORT
Pol Arch Med Wewn. 2011 Oct;121(10):345-50

Wojciechowski P, Ryś P, Lipowska A, Gawęska M, Małecki MT,
Efficacy and safety comparison of continuous glucose monitoring and self-monitoring of blood glucose in type 1 diabetes: systematic review and meta-analysis
REPORT   Pol Arch Med Wewn. 2011 Oct;121(10):333-43. Review

Adamski J, Godman B, Ofierska-Sujkowska G, Osińska B, Herholz H, Wendykowska K, Laius O, Jan S, Sermet C, Zara C, Kalaba M, Gustafsson R, Garuolienè K, Haycox A, Garattini S, Gustafsson LL
Risk sharing arrangements for pharmaceutical: potential considerations and recommendations for European payers
BMC Health Services Research 2010, 10:153
FULL TEXT

Godman B, Shrank W, Wettermark B, Andersen M, Bishop I, Burkhardt T, Garuolienè K, Kalaba M, Laius O, Joppi R, Sermet C, Schwabe U, Teixeira I, CankatTulunay F, Wendykowska K, Zara C,Gustafsson LL
Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
Pharmaceuticals 2010, 3: 2470-2494
ABSTRACT

Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, Garuoliene K, Herholz H, Joppi R, Kalaba M, Laius O, McGinn D, Samaluk V, Sermet C, Schwabe U, Teixeira I, Tilson L, Tulunay FC, Vlahović-Palčevski V, Wendykowska K, Wettermark B, Zara C, Gustafsson LL
Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications
Expert Rev Pharmacoecon Outcomes Res. 2010 Dec;10(6):707-22.
FULL TEXT

Szmurło D, Hetnał M, Ryś P, Skrzekowska-Baran I
Cost-utility analysis of insulin aspart and biphasic insulin aspart in treatment of type 1 and type 2 diabetes.
/Diabetologia Praktyczna/tom 11 nr 1 – 2010
ABSTRACT

Ryś P, Władysiuk M, Skrzekowska-Baran I, Małecki MT.
Review articles, systematic reviews and meta-analyses: which can be trusted?
Pol Arch Med Wewn. 2009 Mar;119(3):148-56.
ABSTRACT, FULL TEXT

Araszkiewicz AA, Szabert K, Godman B, Wladysiuk M, Barbui C, Haycox A.
Generic olanzapine: health authority opportunity or nightmare?
Expert Rev Pharmacoecon Outcomes Res. 2008 Dec;8(6):549-5
ABSTRACT, FULL TEXT

Wieczorek A, Rys P, Skrzekowska-Baran I, Malecki MT.
The role of surrogate endpoints in the evaluation of efficacy and safety of therapeutic interventions in diabetes mellitus
Rev Diabet Stud. 2008 Fall;5(3):128-35.
ABSTRACT, FULL TEXT

Bartosik-Psujek H, Stelmasiak Z, Kozubski W, Pankiewicz O
Efficacy assessment of interferon á-1b and a direct comparison of interferon β-1b with interferon β-1a in treatment of multiple sclerosis.
Aktual. Neurol. 2006: 6 (4) s.224-231.